TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06947928: Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Sponsor: TuHURA Biosciences, Inc. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 118 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$3,720,024

Rescue Site Savings

+$2,480,016

Unlock Full NCT06947928 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06947928 Rescue Dossier →